New hospital policy slashes blood transfusions in major surgeries

NCT ID NCT04803747

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a hospital policy of giving tranexamic acid to adults undergoing major non-cardiac surgery to reduce the need for blood transfusions. Over 8,400 patients took part across multiple hospitals. The goal was to see if this approach safely lowers transfusion rates and blood clot risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

8,421 people

The number who actually took part.

Started

Feb 2022

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Cluster-level inclusion criteria: Hospital sites will be included in the trial if the site performs ≥ 100 noncardiac surgeries per month, and if anesthesia, surgery and hospital leadership agree to manage patients as per the policy being implemented and evaluated in the trial. Patient-level inclusion criteria: * Patients \>/= 18 years of age undergoing major non-cardiac surgery (a state of hyperfibrinolysis) * Inpatient surgeries with an estimated \>/= 5% risk of RBC transfusion, including open surgeries or laparoscopic surgeries with an estimated duration of \>/= 3 hours Examples of eligible surgeries could include (but are not limited to): 1. General surgery (esophagectomy, gastrectomy, gastric repair, small bowel repair or resection, ostomy formation, colon/rectum repair or resection, colostomy, splenectomy, hepatectomy, pancreatectomy, resection of abdominal mass) 2. Orthopedics (hip fracture repair, pelvic fixation, femur repair / fixation, shoulder / humerus open reduction internal fixation, lower extremity amputation) 3. Spine (vertebrectomy, surgery involving \>/= 3 levels) 4. Otolaryngology (glossectomy, mandibulectomy, radical laryngectomy) 5. Thoracic (lung resection or decortication) 6. Vascular (arterial bypass / endarterectomy / aneurysmorrhaphy involving the aorta or proximal vessels off the aorta) 7. Gynecology (hysterectomy) 8. Urology (nephrectomy, cystectomy, prostatectomy, pelvic exenteration) 9. Plastic surgery (large neoplasm resections, burns or debridements) 10. Surgeries anticipated to be associated with 5% or greater risk of RBC transfusion in hospital as per the surgical team. Exclusion Criteria: * Active thromboembolic disease (i.e., arterial or venous thrombosis within 90 days preoperative) * Pregnancy * Cardiac surgery and hip and knee arthroplasty where TXA is standard-of-care * Surgeries with free flap reconstruction * Trauma surgeries where TXA was administered within the previous 3 hours.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major non-cardiac surgeries are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Grace Hospital

    Winnipeg, Manitoba, R3J 3M7, Canada

  • Health Sciences North Research Institute

    Greater Sudbury, Ontario, P3E 5J1, Canada

  • Humber River Hospital

    Toronto, Ontario, M3M 0B2, Canada

  • Hôpital Montfort

    Ottawa, Ontario, K1K 0T2, Canada

  • Kingston Health Sciences Centre

    Kingston, Ontario, K7L 2V7, Canada

  • London Health Sciences Centre

    London, Ontario, N6A 5A5, Canada

  • Ottawa Hospital Research Institute- Civic Campus

    Ottawa, Ontario, K1Y 4E9, Canada

  • Ottawa Hospital Research Institute- General Campus

    Ottawa, Ontario, K1H8L6, Canada

  • St. Boniface Hospital

    Winnipeg, Manitoba, R2H 2A6, Canada

  • University of Manitoba- HSC Campus

    Winnipeg, Manitoba, R3E 0W2, Canada